Protalix BioTherapeutics (PLX) Reports Q2 Loss of $0.11/Share

Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.11), versus ($0.05) reported last year. Revenue for the quarter came in at $1.77 million, versus $1.34 million reported last year.

For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.

You May Also Be Interested In

• TJX stock drops as profit outlook falls short of analyst estimates
• Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
• Target raises full-year sales forecast amid ongoing turnaround drive